{
    "clinical_study": {
        "@rank": "102346", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 3a", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 3b", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/\n      SAR307746) in combination with aflibercept (\"ziv-aflibercept\" in the U.S.)"
        }, 
        "brief_title": "Nesvacumab (REGN910/ SAR307746) and Aflibercept (\"Ziv-aflibercept\" in the U.S.) in Patients With Advanced Solid Malignancies", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Inclusion criteria include, but are not limited to, the following:\n\n          1. Confirmed diagnosis of solid tumor malignancy\n\n          2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n          3. Adequate hepatic, renal and bone marrow function\n\n          4. Resolution of toxicity from prior therapy (except alopecia) to grade less than or\n             equal to 1\n\n        Exclusion Criteria:\n\n        Exclusion criteria include, but are not limited to, the following:\n\n          1. Patients with brain metastases, spinal cord compression, carcinomatous meningitis, or\n             other evidence of central nervous system involvement\n\n          2. Either systolic BP greater than 140 mm Hg or diastolic BP greater than 90 mm Hg\n\n          3. Patients with medical history of myocardial infarction, unstable angina pectoris,\n             coronary/ peripheral artery bypass graft, congestive heart failure or ventricular\n             arrhythmia\n\n          4. Patients with deep vein thrombosis or pulmonary embolism within last 3 months\n\n          5. Patients with serious non healing wound or acute ulcer\n\n          6. Patients with treatment resistant or bleeding peptic ulcer disease, erosive\n             esophagitis or gastritis, grade 3 or gastrointestinal bleeding/hemorrhage, infectious\n             or inflammatory bowel disease, diverticulitis, or other uncontrolled thromboembolic\n             event within last 3 months\n\n          7. Patients with history of abdominal or tracheal-esophageal fistula\n\n          8. Prior treatment with aflibercept (ziv-aflibercept), Ang2 or Tie2 inhibitors\n\n          9. Prior treatment with bevacizumab within last 6 weeks\n\n         10. Pregnant or breast-feeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688960", 
            "org_study_id": "R910-ST-1114"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "Dose level 1", 
                "intervention_name": "nesvacumab (REGN910/ SAR307746)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 2", 
                    "Cohort 3b"
                ], 
                "description": "Dose level 2", 
                "intervention_name": "nesvacumab (REGN910/ SAR307746)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 3a", 
                    "Cohort 4"
                ], 
                "description": "Dose level 3", 
                "intervention_name": "nesvacumab (REGN910/ SAR307746)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3a"
                ], 
                "description": "Dose level 1", 
                "intervention_name": "aflibercept (ziv-aflibercept)", 
                "intervention_type": "Drug", 
                "other_name": "In US: aflibercept is known as ziv-aflibercept"
            }, 
            {
                "arm_group_label": [
                    "Cohort 3b", 
                    "Cohort 4"
                ], 
                "description": "Dose level 2", 
                "intervention_name": "aflibercept (ziv-aflibercept)", 
                "intervention_type": "Drug", 
                "other_name": "In US: aflibercept is known as ziv-aflibercept"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 15, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies", 
        "overall_contact": {
            "email": "clinicaltrials@regeneron.com", 
            "last_name": "Clinical Trials Administrator"
        }, 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the maximum tolerable dose or recommended phase 2 dose of nesvacumab (REGN910/ SAR307746) administered in combination with aflibercept (ziv-aflibercept) in patients with advanced solid malignancies", 
            "measure": "Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D)", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 to Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688960"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess PK parameters such as concentration of nesvacumab (REGN910/ SAR307746) and aflibercept (ziv-aflibercept).", 
                "measure": "Pharmacokinetics (PK)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 170"
            }, 
            {
                "description": "To assess the anti-drug antibodies of nesvacumab (REGN910/ SAR307746) and aflibercept (ziv-aflibercept)", 
                "measure": "Immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 170"
            }, 
            {
                "description": "Objective tumor response according to RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1", 
                "measure": "Antitumor activity", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 170"
            }, 
            {
                "description": "Target inhibition biomarker changes, serum tumor markers", 
                "measure": "Pharmacodynamics (PD)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 170"
            }
        ], 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}